GSPT1 protein degradation agent containing oxime structure as well as preparation method and application of GSPT1 protein degradation agent

By developing GSPT1 protein degrading agents containing oxime structures, the limitations of existing GSPT1 protein degrading agents in the treatment of acute myeloid leukemia and other tumors have been solved, significantly improving the degradation effect and anti-proliferation inhibitory activity of GSPT1 protein, and broadening treatment options.

CN119080738APending Publication Date: 2024-12-06CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310660635.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-06
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing GSPT1 protein degraders have certain limitations in the treatment of tumors such as acute myeloid leukemia, especially the diversity function and complex regulatory mechanism of GSPT1 have not been studied in depth, resulting in limited therapeutic effects.

Method used

A GSPT1 protein degrading agent containing oxime structure was developed. By optimizing the compound's backbone structure, the compounds improve the degradation activity on GSPT1, broaden the anti-proliferative effect of tumor treatment, and provide a wider range of therapeutic options.

Benefits of technology

The degradation effect of GSPT1 protein was significantly improved, and the anti-proliferation inhibitory activity on AML cells was significantly improved. The percentage of compound OX-7 degradation of GSPT1 protein in KG-1 cells was higher than 80%, and it has a time-dependent degradation effect, which broadened the Range of tumor indications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080738A_ABST
    Figure CN119080738A_ABST
Patent Text Reader

Abstract

The invention discloses a compound shown as a general formula I or pharmaceutically acceptable salt, tautomer, meracemate, raceme, enantiomer and diastereoisomer of the compound. The oxime structure-containing compound has excellent GSPT1 degradation activity, can be used as a GSPT1 protein degradation agent, widens the skeleton structure of the GSPT1 molecular glue degradation agent, improves the anti-proliferation effect on tumors, improves the therapeutic window, and provides more choices for research and development of GSPT1 molecular glue. Compared with a clinical drug CC-90009, the oxime compounds such as OX, NX and CX series have the advantage that the degradation effect on GSPT1 protein and the anti-proliferation inhibition activity of AML cells are obviously improved. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of chemical medicine, and in particular relates to a GSPT1 protein degradation agent containing an oxime structure, and a preparation method and application thereof. Background Art

[0002] Targeted protein degradation technology (TPD) is a new technology that interferes with protein function by utilizing the protein degradation mechanism inherent in eukaryotic cells to regulate protein homeostasis. The rise of this technology has to some extent solved the difficulties faced by small molecule inhibitors and gene interference technologies. TPD currently mainly degrades target proteins through ubiquitin proteasomes and lysosomes. Currently, the most mature and most studied in this field are proteolysis-targeting chimeras (PROTACs) and molecular glues (MGs) based on the ubiquitination-proteasome system. Targeted protein degradation technology has broad application prospects and development space in a variety of disease fields, such as malignant tumors, neurodegenerative diseases, metabolic diseases and other fields.

[0003] Molecular glues are small molecules that induce proximity and can provide precise temporal control of various biological processes, such as signal transduction, transcription, chromatin regulation, and protein folding, localization, and degradation. As chemical inducers of proximity, they can induce protein-protein interactions between E3 ubiquitin ligases and target proteins, leading to target protein degradation. Molecular glues can promote dimerization or colocalization of two proteins by forming a ternary complex, resulting in a variety of biological and pharmacological functions.

[0004] G1 to S phase transition 1 (GSPT1, also known as eRF3a) is a translation termination factor in the body. Downregulation of GSPT1 can lead to abnormal expression of key proteins and inhibit proliferation or induce apoptosis in various tumor cells. Since GSPT1 was found to be a new substrate of E3 ubiquitin ligase CRBN, it can be targeted for degradation by molecular glue degraders. Currently, a variety of molecular glue degraders are in clinical and preclinical studies. These molecules are very effective in treating blood tumors and certain solid tumors. GSPT1 is multifunctional. In addition to being a second-class peptide chain release factor and participating in protein translation termination, it is also related to apoptosis, cell cycle regulation, tumor occurrence and development, and other processes. For example, during apoptosis, GSPT1 is processed by proteolysis to form another isoform, which contains a conserved N-terminal apoptosis inhibitor protein binder. GSPT1 interacts with inhibitor of apoptosis proteins (IAPs) through this processed form, releasing the inhibition of IAPs and releasing caspases, thereby promoting cell apoptosis. The M domain of eRF3 interacts with Polya-binding protein (PABP) protein, coupling translation termination and mRNA degradation.

[0005] CC-885, as a 5-substituted isoindoline compound, has strong CRBN-dependent antiproliferative activity in various tumor cell lines, and has enhanced antiproliferative activity compared with lenalidomide and pomalidomide (Nature 2016, 535, 252-257). Immunoprecipitation assays and immunoblotting assays showed that CC-885 promoted the binding of CRBN to the novel substrate GSPT1, targeting its degradation. Using CC-885 as a structural template, a skeleton with difluoroacetamide was discovered through SAR, which showed good selectivity in vitro (J.Med.Chem.2021, 64, 1835-1843). On this basis, BMS / Celgene's third-generation lead compound CC-90009 was further screened out. CC-90009 is a highly efficient GSPT1 selective degrader that shows good PK / PD and safety in the treatment of acute myeloid leukemia and has entered Phase I / II clinical trials (NCT04297124; NCT02848001; NCT04336982).

[0006] Acute myeloid leukemia (AML) is a genetically and biologically heterogeneous myeloid malignancy characterized by abnormal proliferation of immature myeloid progenitor cells, which damages the body's normal hematopoietic function, causing severe infection, anemia, and bleeding. It is characterized by low survival rate and high relapse rate. Therefore, as a relatively rare malignancy, it has been regarded as an orphan disease by the US Food and Drug Administration. GSPT1, as a new substrate of CRL4-CRBN-E3 ubiquitin ligase, plays an important role in the treatment of AML. Clinical drugs targeting GSPT1 for the treatment of AML, such as CC-90009 and BTX-1188, are under development. CC-90009 is mainly used to treat AML by intravenous injection, while BTX-1188 is an oral drug used to treat AML and NHL. Further studies have found that the degradation of GSPT1 is associated with the upregulation of ATF3 and ATF4 gene expression, and ATF3 and ATF4 genes are very important for the integrated stress response pathway. The activation of the integrated stress response pathway is closely related to the phosphorylation of eRF2. When the integrated stress response pathway is activated, it will lead to acute apoptosis of cells.

[0007] In summary, GSPT1 plays an important role in the occurrence and development of related solid tumors. However, due to its diverse functions and complex regulatory mechanisms, it plays different roles in different tumors. However, it is generally recognized that GSPT1 is a proto-oncogene in most tumors, and in certain specific types of tumors, it plays the role of a tumor suppressor gene. At present, there is still a lack of in-depth research on the relevant mechanism of action of GSPT1 in tumors, but there is no doubt that GSPT1 has become a powerful potential target in tumor treatment. Summary of the invention

[0008] Purpose of the invention: The purpose of the present invention is to provide a GSPT1 protein degrading agent containing an oxime structure, and a preparation method and application thereof. The compound containing an oxime structure of the present invention has excellent GSPT1 degradation activity, can be used as a GSPT1 protein degrading agent, broadens the skeleton structure of GSPT1 molecular glue degrading agents, improves the anti-proliferative effect on tumors, improves the therapeutic window, and provides more options for the research and development of GSPT1 molecular glue.

[0009] Technical solution: The purpose of the present invention is achieved through the following technical solution:

[0010] The present invention provides a compound represented by general formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, diastereomer thereof:

[0011]

[0012] in:

[0013] X is selected from -OH, -NH2, -OCH3 or -NHCOCH3;

[0014] Ring Y is selected from C6-C 12 aryl, 5-10 membered heteroaryl, C3-C8 cycloalkyl or 3-10 membered heterocyclyl, wherein the aryl, heteroaryl, cycloalkyl and heterocyclyl are unsubstituted or optionally substituted with 1-3 R a replace;

[0015] R1 is selected from

[0016] R2 is selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O)2R a or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is unsubstituted or optionally substituted with 1-3 R a replace;

[0017] Each R3 is independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O)2R aor a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is unsubstituted or optionally substituted with 1-3 R a replace;

[0018] R4 is selected from hydrogen, deuterium, halogen or C1-C6 alkyl;

[0019] R5 is selected from hydrogen, deuterium, C1-C 12 alkyl,

[0020] Z is selected from -CH2-, -CD2-, -C(O)- or -C(S)-;

[0021] R6, R7, R8, R9, R 10 , R 11 are independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O)2R a or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is unsubstituted or optionally substituted with 1-3 R a replace;

[0022] Each R a , R b are independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, hydroxyl, cyano, nitro, benzyl, -C(O)NR c R d 、-C(O)R c 、-C(O)OR c 、-OR c 、-OC(O)R c 、-OC(O)OR c 、-OC(O)NR c R d 、-NRc R d 、-SR c 、-S(O)R c 、-S(O)2R c or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or benzyl group is unsubstituted or optionally substituted with 1-3 R c replace;

[0023] Each R c , R d Each is independently selected from hydrogen, halogen, carbonyl, hydroxyl, cyano, nitro, phenyl, benzyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 cycloalkyl or halogenated C3-C6 cycloalkyl;

[0024] m, n, and p are independently selected from 0, 1, 2 or 3.

[0025] The compound of the general formula I of the present invention or its pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, diastereomer, preferably a compound having the structure of formula Ia, formula Ib or formula Ic:

[0026]

[0027] wherein X, Y, Z, m, n, and p are as defined in Formula I.

[0028] In certain preferred embodiments,

[0029] X is selected from -OH, -NH2 or -OCH3.

[0030] In certain preferred embodiments,

[0031] R2 is selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O)2Ra ;

[0032] R a , R b are independently selected from hydrogen, C1-C6 alkyl or -C(O)R c ;

[0033] R c is selected from hydrogen, halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy or C3-C6 cycloalkyl;

[0034] Ring Y is selected from C6-C 12 Aryl or 5-10 membered heteroaryl.

[0035] In certain more preferred embodiments,

[0036] R3 is selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, cyano or nitro;

[0037] R4 is selected from hydrogen, deuterium, halogen or C1-C6 alkyl;

[0038] R5 is selected from hydrogen, deuterium or C1-C 12 alkyl;

[0039] m and n are independently selected from 1;

[0040] p is selected from 0 or 1.

[0041] The above-mentioned compounds of general formula I of the present invention may also exist in the form of their salts, which are converted in vivo into compounds of general formula I. For example, within the scope of the present invention, the compounds of the present invention are converted into pharmaceutically acceptable salt forms according to processes known in the art, and they are used in the form of salts.

[0042] In some preferred embodiments, the pharmaceutically acceptable salts include, but are not limited to, acid addition salts formed between the compound of formula I and the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, maleic acid or succinic acid, fumaric acid, salicylic acid, phenylacetic acid, mandelic acid; and also include acid salts formed between the compound of formula I and inorganic bases.

[0043] In some more preferred embodiments, the pharmaceutically acceptable salts include, but are not limited to, basic metal cation salts, alkaline earth metal cation salts, and ammonium cation salts.

[0044] The compounds of the general formula I of the present invention are preferably the following compounds:

[0045]

[0046]

[0047]

[0048] The present invention also provides a method for preparing compounds of formula Ia, Ib, and Ic. The synthetic route is as follows:

[0049]

[0050] The starting material 1 is brominated with N-bromosuccinimide in the presence of a free radical initiator to obtain an intermediate 2; intermediate 2 is substituted with a nucleophilic reagent 3-aminopiperidine-2,6-dione hydrochloride and further formed into a lactam on the ester to obtain an intermediate 3; a cyano group is inserted into the aromatic bromide through palladium mediation to obtain an intermediate 4; followed by reduction and de-tert-butyloxycarbonylation to obtain an intermediate 6, and finally in the presence of a condensation agent EDCI, compounds related to formulas Ia, Ib, and Ic are obtained.

[0051] Another object of the present invention is to provide a pharmaceutical composition, which comprises a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, diastereomer thereof and a pharmaceutically acceptable carrier or excipient.

[0052] The pharmaceutical composition of the present invention can be administered in various known ways, such as orally, parenterally, by inhalation spray or via an implanted reservoir. The pharmaceutical composition of the present invention can be administered alone or in combination with other drugs. Oral compositions can be in any orally acceptable dosage form, including but not limited to tablets, capsules, emulsions, suspensions, dispersions and solutions. Commonly used pharmaceutically acceptable carriers or excipients include stabilizers, diluents, surfactants, lubricants, antioxidants, adhesives, colorants, fillers, emulsifiers, etc.

[0053] Sterile injectable compositions can be formulated using suitable dispersing agents or wetting agents and suspending agents according to techniques known in the art. Pharmaceutically acceptable carriers and solvents that can be used include water, mannitol, sodium chloride solution, and the like.

[0054] The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The dosage level selected depends on a variety of factors, including the activity of the specific compound of the present invention or its salt used, the route of administration, the time of administration, the excretion rate of the specific composition used, the duration of treatment, other drugs, compounds and / or materials used in combination with the specific composition used, the age, sex, weight, general health and previous medical history of the patient being treated, and similar factors well known in the medical field.

[0055] Another object of the present invention is to provide a compound of formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, diastereomer thereof for use in the preparation of a medicament for treating or preventing diseases associated with GSPT1, IKZF1, IKZF2, IKZF3, CK1α, N-MYC or C-MYC protein mutations, expression imbalances, allostery and functional abnormalities.

[0056] The related diseases are cancer, viral infection, aging, immune diseases, and neurological diseases; wherein the cancer is selected from acute myeloid leukemia, liver cancer, acute lymphocytic leukemia, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, chronic lymphocytic leukemia CLL, chronic myeloid leukemia CML, colon cancer, esophageal cancer, gallbladder cancer, gastric cancer, gastrointestinal stromal tumors, head and neck cancer, Hodgkin's lymphoma, laryngeal cancer, leukemia, lung cancer, melanoma, mesothelioma, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, kidney cancer, sarcoma, skin cancer, small cell lung cancer, testicular cancer, pharyngeal cancer, thyroid cancer or uterine cancer.

[0057] The present invention also provides the use of the compound of general formula I or its pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, diastereomer in the preparation of GSPT1 degradation agent.

[0058] The term "isomer" includes enantiomeric, diastereomeric, and geometric (or conformational) isomeric forms of a given structure. For example, the present application includes R and S configurations for each asymmetric center, Z and E double bond isomers, Z and E conformational isomers, single stereochemical isomers and enantiomers, diastereomers, and geometric (or conformational) isomer mixtures.

[0059] The term "pharmaceutically acceptable salt" refers to, for example, acid addition salts and / or base salts thereof. Suitable acid addition salts are formed from acids, which form non-toxic salts, such as hydrochlorides / chlorides. Suitable base salts are formed from bases, which form non-toxic salts, such as calcium and sodium salts. Hemi-salts of acids and bases, such as hemisulphate and hemicalcium salts, can also be formed.

[0060] The term "therapeutically effective amount" refers to an amount of a compound of the invention that (i) treats a specific disease, condition or disorder; (ii) alleviates, relieves or eliminates one or more symptoms of a specific disease, condition or disorder; or (iii) prevents or delays the onset of one or more symptoms of a specific disease, condition or disorder described herein.

[0061] The term "pharmaceutically acceptable carrier or excipient" refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated therewith.

[0062] Beneficial effects:

[0063] Compared with the clinical drug CC-90009, the oxime compounds of the present invention, such as OX, NX, and CX series, have significantly improved degradation effects on GSPT1 protein and anti-proliferation inhibitory activity of AML cells. Among them, 200nM compound OX-7 was administered to KG-1 cells for 4 hours, and the degradation percentage of GSPT1 protein was higher than 80%. Under the same conditions, the degradation percentage of GSPT1 protein by compound NX-7 was higher than 90%. Compared with the clinical drug CC-90009, compounds OX-7 and NX-7 can also significantly degrade C-MYC protein; compound OX-7 can also significantly induce the production of c-PARP protein, has a significant effect of inducing cell apoptosis, and broadens the scope of tumor indications. At a dosing concentration of 100nM, compound OX-7 began to have a significant degradation effect on GSPT1 and C-MYC at 2h, and as time goes by, the degradation effect is better, showing a significant time dependence. Therefore, the compounds of the present invention can be used to prepare drugs for treating or preventing diseases associated with GSPT1, IKZF1, IKZF2, IKZF3, CK1α, N-MYC or C-MYC protein mutations, expression imbalances, conformational changes and functional abnormalities; and can be used to prepare GSPT1 degraders. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Figure 1 The compound OX-7 of the present invention has a concentration-dependent effect on the degradation of GSPT1 in AML cells. Figure 1 A is the degradation effect of compound OX-7 and clinical drug CC-90009 on GSPT1 in KG-1 cells; Figure 1 B shows the degradation effect of compound OX-7 and clinical drug CC-90009 on GSPT1 in MOLM-13 cells.

[0065] Figure 2 The degradation effect of the compound OX-7 of the present invention on GSPT1 in AML cells is time-dependent.

[0066] Figure 3The antiproliferation activity of the compound OX-7 of the present invention and the clinical drug CC-90009 on different tumor cells. Figure 3 A and 3B are the antiproliferative activities of OX-7 and CC-90009 on KG-1 cells, respectively; Figure 3 C and 3D are the antiproliferative activities of OX-7 and CC-90009 on MOLM-13 cells, respectively. DETAILED DESCRIPTION

[0067] The technical solution of the present invention is described in detail below through specific embodiments, but the protection scope of the present invention is not limited to the embodiments.

[0068] Synthesis of key intermediate-1:

[0069]

[0070] Step 1: Dissolve methyl 4-bromo-2-methylbenzoate (10.00 g, 43.86 mmol) in 200 mL of carbon tetrachloride, add N-bromosuccinimide (15.61 g, 87.73 mmol) and azobisisobutyronitrile (0.72 g, 4.38 mmol) in sequence, and heat to reflux and stir for 12 hours. The reaction is complete as monitored by TLC, and the mixture is cooled to room temperature and filtered. The filtrate is concentrated in vacuo, and the residue is purified by silica gel chromatography (DCM: MeOH = 40: 1, v / v) to obtain a white solid methyl 2:4-bromo-2-(bromomethyl)benzoate (8.32 g, yield 62.0%).

[0071] HRMS(ESI + Calculated value: C9H9Br2O2(M+H) + ,306.8964; measured value 306.8958.

[0072] Step 2: Dissolve methyl 4-bromo-2-(bromomethyl)benzoate (8.00 g, 26.15 mmol) in 60 mL of N,N-dimethylformamide, add 3-aminopiperidine-2,6-dione hydrochloride (5.15 g, 31.38 mmol) and DIPEA (8.45 g, 65.38 mmol) in sequence, and heat to 90°C under nitrogen protection and stir for 4 hours. The reaction is complete as monitored by TLC, and the reaction solution is poured into 200 mL of water to precipitate a light blue solid, which is allowed to stand for complete precipitation, and then filtered. The filter cake is vacuum dried to obtain a light blue solid 3: 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (5.89 g, yield 70.2%).

[0073] HRMS(ESI + ): Calculated value C 13 H12 BrN2O3(M+H) + ,323.0026; measured value 323.0030.

[0074] Step 3: Dissolve 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (5.00 g, 15.53 mmol) in 50 mL of dry N,N-dimethylformamide, and add 1,1'-bis(diphenylphosphino)ferrocene (0.40 g, 0.71 mmol), tris(dibenzylideneacetone)dipalladium (0.39 g, 0.43 mmol) and zinc cyanide (1.88 g, 16.00 mmol) in sequence. After the addition is complete, heat to 90°C and stir for 4 hours under nitrogen protection. The reaction was complete as monitored by TLC, and the reaction was filtered with suction. The filtrate was poured into 150 mL of water to precipitate a green solid. The solid was allowed to stand for complete precipitation, and then filtered with suction. The filter cake was dried under vacuum to obtain a light green solid 4: 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carbonitrile (3.84 g, yield 91.9%).

[0075] HRMS(ESI + ): Calculated value C 14 H 12 N3O3(M+H) + ,270.0873; measured value 270.0882.

[0076] Step 4: 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carbonitrile (3.50 g, 13.00 mmol) was dissolved in 40 mL of N,N-dimethylformamide, and di-tert-butyl dicarbonate (5.67 g, 26.00 mmol) and 15 mL of Raney nickel were added in sequence. After the addition was completed, the mixture was heated to 50°C and stirred for 5 hours under full replacement of hydrogen. The reaction was monitored by TLC, and the filter cake was washed with ethyl acetate. The filtrate was poured into 120 mL of water, extracted with ethyl acetate, and the organic phases were combined and washed with water and saturated brine in sequence. After drying over anhydrous sodium sulfate, the mixture was concentrated in vacuo to obtain a brown solid 5: tert-butyl ((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)methyl)carbamate (3.20 g, yield 65.9%), which can be directly used in the next step without further purification.

[0077] HRMS(ESI + ): Calculated value C 19 H 24 N3O5(M+H) + ,374.1710; measured value 374.1721.

[0078] Step 5: Dissolve tert-butyl ((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)carbamate (3.00 g, 8.04 mmol) in 30 mL of hydrochloric acid-dioxane solution (4 M) and stir at room temperature for 3 hours. The reaction was complete as monitored by TLC, and the filter cake was vacuum-dried to obtain a light yellow solid, which was intermediate-1: 3-(5-aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (1.80 g, yield 72.4%), which can be directly used in the next step without further purification.

[0079] HRMS(ESI + ): Calculated value C 14 H 16 N3O3(M+H) + ,274.1186; measured value 274.1184.

[0080] Synthesis of key intermediate-2 and intermediate-3:

[0081]

[0082] Step 1: Benzaldehyde (2.00 g, 18.86 mmol) was dissolved in 20 mL of acetic anhydride, and N-acetylglycine (3.31 g, 28.29 mmol) and sodium acetate (2.32 g, 28.29 mmol) were added in sequence, and the mixture was heated to 120°C and stirred for 5 hours. The reaction was complete as monitored by TLC, and the reaction solution was cooled to room temperature to precipitate an orange-yellow solid, which was allowed to stand in an ice bath to precipitate completely, and then filtered, and the filter cake was dried in vacuo to obtain a yellow solid 7: (Z)-4-benzylidene-2-methyloxazol-5(4H)-one (2.2 g, yield 62.5%), which was used directly in the next step without further purification.

[0083] HRMS(ESI + ): Calculated value C 11 H 10 NO2(M+H) + ,188.0706; measured value 188.0718.

[0084] Step 2: (Z)-4-benzylidene-2-methyloxazol-5(4H)-one (2.20 g, 11.76 mmol) was dissolved in 50 mL of 10% hydrochloric acid aqueous solution, heated to 100°C and stirred for 10 hours. The reaction was complete as monitored by TLC, and the reaction solution was cooled to room temperature. A brown solid was precipitated under ice bath, and the precipitation was complete after standing. The solid was filtered and the filter cake was dried under vacuum to obtain a brown solid, which was intermediate-2: 2-oxo-3-phenylpropionic acid (1.52 g, yield 78.7%). The product can be used directly in the next step without further purification.

[0085] HRMS(ESI - ): Calculated value C9H7O3(MH) - ,163.0401; measured value 163.0412.

[0086] Step 3: 2-oxo-3-phenylpropionic acid (1.52 g, 9.27 mmol) was dissolved in 20 mL of pyridine, and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (1.30 g, 11.12 mmol) was added, and stirred at room temperature for 12 hours under nitrogen protection. The reaction was complete as monitored by TLC, and the reaction solution was poured into 1N hydrochloric acid solution, extracted with ethyl acetate, and the combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to obtain a brown solid, which was intermediate-3: (E)-3-phenyl-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propionic acid (1.95 g, yield 80.0%).

[0087] HRMS(ESI - ): Calculated value C 14 H 16 NO4(MH) - ,262.1085; measured value 262.1079.

[0088] Synthesis of key intermediate-4:

[0089]

[0090] Step 1: 2-oxo-3-phenylpropionic acid (1.52 g, 9.26 mmol) was dissolved in 20 mL of pyridine, methoxyamine hydrochloride (1.16 g, 13.89 mmol) was added, and the mixture was stirred at room temperature for 12 hours under nitrogen protection. The reaction was complete as monitored by TLC, and the reaction solution was poured into 1N hydrochloric acid solution, extracted with ethyl acetate, and the organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to obtain a brown solid, which was intermediate-4: (E)-2-(methoxyimino)-3-phenylpropionic acid (1.21 g, yield 67.9%).

[0091] HRMS(ESI - ): Calculated value C 10 H 10 NO3(MH) - ,192.0666; measured value 192.0678.

[0092] Synthesis of key intermediate-5:

[0093]

[0094] Step 1: Dissolve 5-nitroisobenzofuran-1,3-dione (14.50 g, 75.00 mmol) in 20 mL of acetic acid solution, add 3-aminopiperidine-2,6-dione hydrochloride (8.20 g, 50.00 mmol) and sodium acetate (5.00 g, 60.00 mmol) in turn, heat to reflux and stir for 5 h. The reaction was complete as monitored by TLC. After the reaction solution was cooled to room temperature, it was poured into 100 mL of ice water to precipitate a white solid. The solution was allowed to stand for complete precipitation, filtered, and the filter cake was vacuum dried to obtain an off-white solid 9: 2-(2,6-dioxopiperidin-3-yl)-5-nitroisoindoline-1,3-dione (9.03 g, yield 62.4%). HRMS (ESI + ): Calculated value C 13 H 10 N3O6(M+H) + ,304.0564; measured value 304.0575.

[0095] Step 2: Dissolve 2-(2,6-dioxopiperidin-3-yl)-5-nitroisoindoline-1,3-dione (3.63 g, 11.98 mmol) in 10 mL of N,N-dimethylformamide, add 10% palladium carbon (0.54 g, 5.07 mmol), and stir at room temperature for 12 hours under full replacement of hydrogen. The reaction is complete as monitored by TLC, and the filtrate is filtered and poured into 100 mL of ice water to precipitate a yellow solid. Let it stand to precipitate completely, filter, and vacuum dry the filter cake to obtain a yellow solid, which is intermediate 5: 5-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (3.00 g, yield 92.0%). HRMS (ESI + ): Calculated value C 13 H 12 N3O4(M+H) + ,274.0822; calculated value 274.0834.

[0096] Synthesis of clinical drug CC-90009:

[0097]

[0098] 3-(5-aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (0.10 g, 0.32 mmol) was dissolved in 5 mL of N,N-dimethylformamide, and 2-(4-chlorophenyl)-2,2-difluoroacetic acid (0.08 g, 0.39 mmol) and HATU (0.19 g, 0.49 mmol) were added in sequence. After the addition was completed, the mixture was stirred at room temperature for 1 hour. DIPEA (0.13 g, 0.97 mmol) was added and stirred at room temperature overnight. The reaction was monitored by TLC. The reaction solution was poured into 30 mL of ice water to precipitate a brown solid. The solid was allowed to stand for complete precipitation, and then filtered. The filter cake was purified using a silica gel column (dichloromethane: methanol = 50: 1, v / v) to obtain a white solid CC-90009 (0.10 g, yield 68.0%, purity 99.37%).

[0099] 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.00 (s, 1H), 9.70 (t, J = 6.1Hz, 1H), 7.68 (d, J = 7.8Hz, 1H), 7.62 (s, 4H), 7.41 (s, 1H), 7.37 (d, J = 7.8Hz, 1H),5.11(dd,J=13.3,5.0Hz,1H),4.53-4.22(m,4H),3.02-2.83(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.30(m,1H),2.06-1.94(m,1H).

[0100] HRMS(ESI + ): Calculated value C 22 H 19 ClF2N3O4(M+H) + ,462.1027; measured value 462.1025.

[0101] Example 1: Synthesis of Compound OX-1: (E)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)-3-phenylpropionamide

[0102]

[0103] Step 1: Dissolve (E)-3-phenyl-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propionic acid (Intermediate-3, 2.00 g, 7.60 mmol) in 10 mL of N,N-dimethylformamide, add EDCI (2.18 g, 11.40 mmol) and HOBT (1.54 g, 11.40 mmol) in turn, stir at room temperature for 1 hour after addition. Add 3-(5-aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (1.17 g, 3.80 mmol) and stir at room temperature overnight. The reaction was completed as monitored by TLC. The reaction solution was poured into 30 mL of water and extracted with ethyl acetate. The organic phases were combined and washed with water and saturated brine in sequence. After drying over anhydrous sodium sulfate, the product was concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane:methanol=50:1, v / v) to give a light yellow solid 10: (E)-N-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindol-5-yl)methyl)-3-phenyl-2-((tetrahydro-2H-pyran-2-yl)oxy)imine)propanamide (1.01 g, yield 51.0%).

[0104] Step 2: Compound 10 (0.50 g, 0.96 mmol) was dissolved in 10 mL of hydrochloric acid-dioxane solution (4 M) and stirred at room temperature for 3 hours. The reaction was completed as monitored by TLC, and the mixture was filtered and the filter cake was purified by methanol slurry and vacuum dried to obtain a white solid OX-1 (0.20 g, yield 47.6%, purity 98.61%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.96 (s, 1H), 11.02 (s, 1H), 8.70 (t, J = 6.3Hz, 1H), 7.82 (d, J = 7.7Hz, 1H), 7.45 (s, 1H), 7.35-7.20 (m, 5H), 7.13 (s, 1 H),5.11(dd,J=13.3,5.0Hz,1H),4.50-4.21(m,4H),3.85(s,2H),3.00-2 .83(m,1H),2.60(d,J=17.6Hz,1H),2.47-2.32(m,1H),2.07-1.96(m,1H).

[0105] HRMS(ESI + ): Calculated value C 23 H 23 N4O5(M+H) + ,435.1663; measured value 435.1658.

[0106] Example 2: Synthesis of Compound OX-2: (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(4-fluorophenyl)-2-(hydroxyimino)propionamide

[0107]

[0108] According to the synthesis method of intermediate-3, the starting material benzaldehyde was replaced with p-fluorobenzaldehyde to obtain compound 11: (E)-3-(4-fluorophenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid. The total yield of the three steps was 73.7%.

[0109] HRMS(ESI - ): Calculated value C 14 H 15 FNO4(MH) - ,280.0991; measured value 280.0987.

[0110] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 11 to obtain compound 12; compound 10 was replaced by compound 12 to obtain white solid OX-2: (0.18 g, yield 42.8%, purity 99.40%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.95 (s, 1H), 11.02 (s, 1H), 8.70 (t, J = 6.3Hz, 1H) ,7.66(d,J=7.7Hz,1H),7.39(s,1H),7.35(d,J=7.8Hz,1H),7.31-7.18(m,2H),7 .16-7.04(m,2H),5.11(dd,J=13.3,5.0Hz,1H),4.50-4.21(m,4H),3.82(s,2H), 3.02-2.83(m,1H),2.60(d,J=18.0Hz,1H),2.47-2.31(m,1H),2.07-1.94(m,1H).

[0111] HRMS(ESI + ): Calculated value C 23 H 22 FN4O5(M+H) + ,453.1569; measured value 453.1566.

[0112] Example 3 Compound OX-3: Synthesis of (E)-3-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)propionamide

[0113]

[0114] According to the synthesis method of intermediate-3, the starting material benzaldehyde was replaced with p-chlorobenzaldehyde to obtain compound 13: (E)-3-(4-chlorophenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid. The total yield of the three steps was 49.6%. HRMS (ESI - ): Calculated value C 14 H 15 ClNO4(MH) - ,296.0695; measured value 296.0688.

[0115] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 13 to obtain compound 14: Compound 10 was replaced by compound 14 to obtain white solid OX-3 (0.15 g, yield 35.7%, purity 99.02%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.99 (s, 1H), 11.02 (s, 1H), 8.71 (t, J = 6.3Hz, 1H), 7.66 (d, J = 7.7Hz, 1H), 7.39-7.31 (m, 4H), 7.23 (d, J = 8.3Hz, 2H) ,5.11(dd,J=13.3,5.0Hz,1H),4.50-4.20(m,4H),3.83(s,2H),3.01-2. 84(m,1H),2.60(d,J=17.3Hz,1H),2.48-2.29(m,1H),2.06-1.94(m,1H).

[0116] HRMS(ESI + ): Calculated value C 23 H 22 ClN4O5(M+H) + ,469.1273; measured value 469.1268.

[0117] Example 4 Compound OX-4: Synthesis of (E)-3-(4-bromophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)propionamide

[0118]

[0119] According to the synthesis method of intermediate-3, the starting material benzaldehyde was replaced with p-bromobenzaldehyde to obtain compound 15: (E)-3-(4-bromophenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid. The total yield of the three steps was 40.3%. HRMS (ESI - ): Calculated value C 14 H 15 BrNO4(MH) - ,340.0190; measured value 340.0186.

[0120] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 15 to obtain compound 16: Compound 10 was replaced by compound 16 to obtain white solid OX-4 (0.17 g, yield 39.5%, purity 98.97%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.97 (s, 1H), 11.00 (s, 1H), 8.68 (t, J = 6.3Hz, 1H ),7.66(d,J=7.7Hz,1H),7.47(d,J=8.4Hz,2H),7.35(d,J=8.4Hz,2H),7.17(d, J=8.3Hz,2H),5.11(dd,J=13.2,5.0Hz,1H),4.50-4.18(m,4H),3.81(s,2H),3. 02-2.83(m,1H),2.60(d,J=17.6Hz,1H),2.44-2.29(m,1H),2.08-1.93(m,1H). HRMS(ESI + ): Calculated value C 23 H 22 BrN4O5(M+H) + ,513.0768; measured value 513.0767.

[0121] Example 5 Compound OX-5: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)-3-(4-nitrophenyl)propionamide

[0122]

[0123] According to the synthesis method of intermediate-3, the starting material benzaldehyde was replaced with p-nitrobenzaldehyde to obtain compound 17: (E)-3-(4-nitrophenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propionic acid. The total yield of the three steps was 51.3%. HRMS (ESI - ): Calculated value C 14 H15 N2O6(MH) - ,307.0936; measured value 307.0929.

[0124] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 17 to obtain compound 18: Compound 10 was replaced by compound 18 to obtain white solid OX-5 (0.14 g, yield 32.5%, purity 96.83%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 12.12 (s, 1H), 10.99 (s, 1H), 8.74 (t, J = 6.3Hz, 1H), 8.16(d,J=8.7Hz,2H),7.66(d,J=7.8Hz,1H),7.48(d,J=8.6Hz,2H),7.41(s,1H),7 .37(d,J=7.8Hz,1H),5.10(dd,J=13.2,5.0Hz,1H),4.51-4.21(m,4H),3.97(s,2H) ,3.00-2.89(m,1H),2.60(d,J=16.9Hz,1H),2.46-2.28(m,1H),2.05-1.95(m,1H). HRMS(ESI + ): Calculated value C 23 H 22 N5O7(M+H) + ,480.1514; measured value 480.1510.

[0125] Example 6 Compound OX-6: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)-3-(4-morpholinophenyl)propionamide

[0126]

[0127] According to the synthesis method of intermediate-3, the starting material benzaldehyde was replaced with 4-(4-morpholine)benzaldehyde to obtain compound 19: (E)-3-(4-morpholinephenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid. The total yield of the three steps was 47.6%. HRMS (ESI - ): Calculated value C 18 H 23 N2O5(MH) - ,347.1612; measured value 347.1621.

[0128] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 19 to obtain compound 20; compound 10 was replaced by compound 20 to obtain white solid OX-6 (0.15 g, yield 34.8%, purity 95.80%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.79 (s, 1H), 11.00 (s, 1H), 8.62 (t, J = 6.3Hz, 1H), 7.65 (d, J =7.8Hz,1H),7.38(s,1H),7.33(d,J=7.9Hz,1H),7.09(s,1H),7.06(s,1H),6.85(s,1H),6. 82(s,1H),5.11(dd,J=13.3,5.0Hz,1H),4.49-4.20(m,4H),3.77-3.68(m,6H),3.03(t,J=4 .8Hz,4H),2.98-2.83(m,1H),2.60(d,J=17.1Hz,1H),2.45-2.28(m,1H),2.04-1.93(m,1H).

[0129] HRMS(ESI + ): Calculated value C 27 H 30 N5O6(M+H) + ,520.2191; measured value 520.2185.

[0130] Example 7 Compound OX-7: Synthesis of (E)-3-(3-chloro-4-methylphenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)propionamide

[0131]

[0132] According to the synthesis method of Intermediate-3, the starting material benzaldehyde was replaced with 3-chloro-4-methylbenzaldehyde to obtain Compound 21: (E)-3-(3-chloro-4-methylphenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid. The total yield of the three steps was 49.6%.

[0133] HRMS(ESI - ): Calculated value C 15 H 17 ClNO4(MH) - ,310.0852; measured value 310.0847.

[0134] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 21 to obtain compound 22; compound 10 was replaced by compound 22 to obtain white solid OX-7 (0.17 g, yield 37.2%, purity 99.05%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.96 (s, 1H), 10.99 (s, 1H), 8.69 (t, J = 6.3Hz, 1H), 7.65 (d, J=7.8Hz,1H),7.40(s,1H),7.35(d,J=7.8Hz,1H),7.24(d,J=7.8Hz,1H),7.22(s,1H),7.0 7(d,J=7.9,1.8Hz,1H),5.11(dd,J=13.3,5.1Hz,1H),4.49-4.21(m,4H),3.80(s,2H),3.0 1-2.83(m,1H),2.60(d,J=17.4Hz,1H),2.47-2.31(m,1H),2.27(s,3H),2.05-1.98(m,1H).

[0135] HRMS(ESI + ): Calculated value C 24 H 24 ClN4O5(M+H) + ,483.1430; measured value 483.1426.

[0136] Example 8 Compound OX-8: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)-3-(4-(trifluoromethoxy)phenyl)propanamide

[0137]

[0138] According to the synthesis method of intermediate-3, the starting material benzaldehyde was replaced with p-trifluoromethoxybenzaldehyde to obtain compound 23: (E)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid. The total yield of the three steps was 51.3%.

[0139] HRMS(ESI - ): Calculated value C 15 H 15 F3NO5(MH) - ,346.0908; measured value 346.0911.

[0140] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 23 to obtain compound 24; compound 10 was replaced by compound 24 to obtain white solid OX-8 (0.11 g, yield 25.6%, purity 98.88%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.88 (s, 1H), 11.00 (s, 1H), 8.65 (t, J = 6.3Hz, 1H) ,7.64(d,J=7.7Hz,1H),7.41(s,1H),7.34(d,J=7.8Hz,1H),7.27-7.15(m,2H),7 .08-6.90(m,2H),5.11(dd,J=13.3,5.0Hz,1H),4.50-4.21(m,4H),3.81(s,2H), 3.02-2.84(m,1H),2.60(d,J=17.5Hz,1H),2.48-2.31(m,1H),2.07-1.93(m,1H).

[0141] HRMS(ESI + ): Calculated value C 24 H 22 F3N4O6(M+H) + ,519.1486; measured value 519.1482.

[0142] Example 9 Compound OX-9: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)-3-(4-(trifluoromethyl)phenyl)propanamide

[0143]

[0144] According to the synthesis method of intermediate-3, the starting material benzaldehyde was replaced with p-trifluoromethylbenzaldehyde to obtain compound 25: (E)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)-3-(4-(trifluoromethyl)phenyl)propanoic acid. The total yield of the three steps was 45.3%. HRMS (ESI - ): Calculated value C 15 H 15 F3NO4(MH) - ,330.0959; measured value 330.0961.

[0145] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 25 to obtain compound 26; compound 10 was replaced by compound 26 to obtain yellow solid OX-9 (0.12 g, yield 27.9%, purity 98.43%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.95 (s, 1H), 11.05 (s, 1H), 8.67 (t, J = 6.3Hz, 1H), 7.64 (d, J = 7.7Hz, 1H), 7.50-7.32 (m, 4H), 7.25-7.13 (m, 2H), 5.11(dd,J=13.3,5.0Hz,1H),4.51-4.22(m,4H),3.78(s,2H),2.99-2.8 3(m,1H),2.60(d,J=17.5Hz,1H),2.47-2.32(m,1H),2.08-1.94(m,1H).

[0146] HRMS(ESI + ): Calculated value C 24 H 22 F3N4O5(M+H) + ,503.1537; measured value 503.1532.

[0147] Example 10 Compound OX-10: Synthesis of (E)-3-([1,1'-biphenyl]-4-yl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)propionamide 7

[0148]

[0149] According to the synthesis method of intermediate-3, the starting material benzaldehyde was replaced with p-phenylbenzaldehyde to obtain compound 27: (E)-3-([1,1'-biphenyl]-4-yl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid. The total yield of the three steps was 43.6%. HRMS (ESI - ): Calculated value C 20 H 20 NO4(MH) - ,338.1398; measured value 338.1390.

[0150] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 27 to obtain compound 28; compound 10 was replaced by compound 28 to obtain light yellow solid OX-10 (0.10 g, yield 23.3%, purity 97.28%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.90 (s, 1H), 11.05 (s, 1H), 8.70 (t, J = 6.3Hz, 1H), 7.80-7.65 (m, 4H), 7.55-7.38 (m, 4H), 7.33 (s, 1H) 7.25-7.06 (m, 3 H),5.11(dd,J=13.3,5.0Hz,1H),4.56-4.23(m,4H),3.83(s,2H),3.00-2 .83(m,1H),2.60(d,J=17.7Hz,1H),2.48-2.32(m,1H),2.07-1.95(m,1H). HRMS(ESI + ): Calculated value C 29 H 27 N4O5(M+H) + ,511.1976; measured value 511.1972.

[0151] Example 11: Synthesis of Compound OX-11: (E)-3-(3-chloro-4-methylphenyl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-(hydroxyimino)propionamide

[0152]

[0153] Step 1: (E)-3-(3-chloro-4-methylphenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid (Compound 21, 1.25 g, 4.03 mmol) was dissolved in 10 mL of N,N-dimethylformamide, and EDCI (1.05 g, 5.49 mmol) and HOBT (0.74 g, 5.49 mmol) were added in sequence. After the addition was completed, the mixture was stirred at room temperature for 1 hour. 5-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (1.0 g, 3.66 mmol) was added and stirred at room temperature overnight. The reaction was completed as monitored by TLC. The reaction solution was poured into 50 mL of water and cooled to precipitate a yellow solid. The product was filtered off with suction and the filter cake was dried. The residue was purified using a silica gel column (dichloromethane:methanol=60:1, v / v) to give a yellow solid 29: (E)-3-(3-chloro-4-methylphenyl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanamide (1.07 g, yield 50.2%).

[0154] Step 2: Compound 29 (0.20 g, 0.35 mmol) was dissolved in 10 mL of hydrochloric acid-dioxane solution (4 M) and stirred at room temperature for 20 hours. The reaction was completed as monitored by TLC, the reaction solution was concentrated in vacuo and dried, and the residue was purified using a silica gel column (dichloromethane: methanol = 60: 1, v / v) to obtain a yellow-white solid OX-11 (0.13 g, yield 75.0%, purity 97.77%). 1 HNMR(300MHz,DMSO-d6)δ(ppm)12.40(s,1H),11.13(s,1H),10.64(s,1H),8.34(s,1H),8.20-8.11(m,1H),7.89(d,J=8.2Hz,1H),7.32-7.22(m ,2H),7.14(d,J=7.8Hz,1H),5.13(dd,J=12.9,5.3Hz,1H),3.90(s,2H) ,2.98-2.80(m,1H),2.66-2.53(m,2H),2.27(s,3H),2.11-2.00(m,1H). HRMS(ESI + ): Calculated value C 23 H 20 ClN4O6(M+H) + ,483.1066; measured value 483.1060.

[0155] Example 12: Synthesis of Compound OX-12: (E)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3-(4-fluorophenyl)-2-(hydroxyimino)propionamide

[0156]

[0157] According to the synthesis method of compound OX-11 in Example 11, the starting material compound 21 was replaced by compound 11: (E)-3-(4-fluorophenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid to obtain compound 30; compound 29 was replaced by compound 30 to obtain light yellow solid OX-12 (0.10 g, yield 58.8%, purity 96.95%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 12.05 (s, 1H), 11.03 (s, 1H), 10.58 (s, 1H), 8.30 (s, 1H), 8.20-8.09 (m, 1H), 7.95 (d, J = 8.2Hz, 1H), 7.40-7.28 (m, 1H) ),7.24-7.08(m,3H),5.13(dd,J=12.9,5.3Hz,1H),3.88(s,2H),2.98-2. 82(m,1H),2.59(d,J=17.5Hz,1H),2.48-2.32(m,1H),2.09-1.94(m,1H). HRMS(ESI + ): Calculated value C 22 H 18 FN4O6(M+H) + ,453.1205; measured value 453.1200.

[0158] Example 13 Compound OX-13: Synthesis of (E)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-(hydroxyimino)-3-(4-(trifluoromethyl)phenyl)propanamide

[0159]

[0160] According to the synthesis method of compound OX-11 in Example 11, the starting material compound 21 was replaced by compound 25: (E)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)-3-(4-(trifluoromethyl)phenyl)propanoic acid to obtain compound 31; compound 29 was replaced by compound 31 to obtain light yellow solid OX-13 (0.09 g, yield 52.9%, purity 97.29%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 12.01 (s, 1H), 10.98 (s, 1H), 10.44 (s, 1H), 8.33 (s, 1H), 8.15-8.04 (m, 1H), 7.95 (d, J = 8.2Hz, 1H), 7.48-7.32 (m, 1H) ),7.23-7.08(m,3H),5.11(dd,J=12.9,5.3Hz,1H),3.90(s,2H),3.00-2. 82(m,1H),2.60(d,J=17.7Hz,1H),2.48-2.32(m,1H),2.10-1.96(m,1H). HRMS(ESI + ): Calculated value C 23 H 18 F3N4O6(M+H) +,503.1173; measured value 503.1168.

[0161] Example 14 Synthesis of Compound NX-1: (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-hydrazinylidene-3-phenylpropanamide

[0162]

[0163] Step 1: Dissolve 2-oxo-3-phenylpropionic acid (Intermediate-2, 1.06 g, 6.47 mmol) in 10 mL of N,N-dimethylformamide, add EDCI (1.24 g, 6.47 mmol) and HOBT (0.87 g, 6.47 mmol) in turn, stir at room temperature for 1 hour after addition. Add 3-(5-aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (1.00 g, 3.23 mmol) and stir at room temperature overnight. The reaction was completed as monitored by TLC, and the reaction solution was poured into 50 mL of water and extracted with ethyl acetate. The organic phases were combined and washed with water and saturated brine in sequence, dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane:methanol=65:1, v / v) to give a brown solid 32: N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxo-3-phenylpropanamide (0.83 g, yield 59.0%).

[0164] Step 2: Compound 32 (0.50 g, 1.15 mmol) was dissolved in 10 mL of acetic acid solution (50%), 80% hydrazine hydrate (0.07 g, 1.15 mmol) was added, and the mixture was stirred at room temperature for 5 h. The reaction was completed as monitored by TLC. The reaction solution was poured into 50 mL of saturated sodium bicarbonate solution, extracted with ethyl acetate, and the organic phases were combined and washed with water and saturated brine in sequence. After drying over anhydrous sodium sulfate, the mixture was concentrated in vacuo. The residue was purified by silica gel chromatography (dichloromethane: methanol = 70: 1, v / v) to give a light yellow solid NX-1 (0.15 g, yield 30.0%, purity 98.37%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.00 (s, 1H), 8.49 (t, J = 6.4Hz, 1H), 7.82 (d, J =7.8Hz,1H),7.51(s,1H),7.38(d,J=9.1Hz,1H),7.30(s,3H),7.21(s,2H),6. 62(s,2H),5.13(dd,J=13.3,5.1Hz,1H),4.50-4.25(m,4H),3.81(s,2H),2.9 9-2.85(m,1H),2.60(d,J=17.0Hz,1H),2.47-2.33(m,1H),2.08-1.94(m,1H). HRMS(ESI + ): Calculated value C 23 H 24 N5O4(M+H) + ,434.1823; measured value 434.1816.

[0165] Example 15 Synthesis of Compound NX-2: N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-3-(4-fluorophenyl)-2-oxopropanamide

[0166]

[0167] According to the synthesis method of intermediate-2, the starting material benzaldehyde was replaced with p-fluorobenzaldehyde to obtain compound 33: 3-(4-fluorophenyl)-2-oxopropanoic acid. The total yield of the two steps was 68.5%. HRMS (ESI - ): Calculated value C9H6FO3(MH) - ,181.0306; measured value 181.0306.

[0168] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 33 to obtain compound 34; compound 32 was replaced by compound 34 to obtain yellow solid NX-2 (0.13 g, yield 26.0%, purity 99.60%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 10.99 (s, 1H), 8.39 (t, J = 6.4Hz, 1H), 7.75 (d, J = 7.8Hz, 1H), 7.50 (s, 1H), 7.38-7.22 (m, 3H), 7.15-7.04 (m, 2H), 6.49 (s ,2H),5.13(dd,J=13.3,5.1Hz,1H),4.50-4.23(m,4H),3.75(s,2H),3.00- 2.83(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.32(m,1H),2.08-1.94(m,1H). HRMS(ESI + ): Calculated value C 23 H 23 FN5O4(M+H) + ,452.1729; measured value 452.1726.

[0169] Example 16: Synthesis of Compound NX-3: N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxo-3-(p-tolyl)propanamide

[0170]

[0171] According to the synthesis method of intermediate-2, the starting material benzaldehyde was replaced with p-methylbenzaldehyde to obtain compound 35: 2-oxo-3-(p-tolyl)propionic acid. The total yield of the two steps was 65.3%. HRMS (ESI - ): Calculated value C 10 H9O3(MH) - ,177.0557; measured value 177.0568.

[0172] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 35 to obtain compound 36; compound 32 was replaced by compound 36 to obtain brown solid NX-3 (0.17 g, yield 34.0%, purity 97.49%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.05 (s, 1H), 8.45 (t, J=6.4Hz, 1H), 7.75 (d, J= 7.8Hz,1H),7.50(s,1H),7.34-7.20(m,3H),7.12-7.02(m,2H),6.45(s,2H),5 .11(dd,J=13.3,5.1Hz,1H),4.50-4.23(m,4H),3.75(s,2H),3.00-2.85(m,1H ), 2.60 (d, J = 17.5Hz, 1H), 2.47-2.32 (m, 1H), 2.20 (s, 3H), 2.07-1.92 (m, 1H). HRMS(ESI + ): Calculated value C 24 H 26 N5O4(M+H) + ,448.1980; measured value 448.1976.

[0173] Example 17: Synthesis of Compound NX-4: N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxo-3-(4-(trifluoromethoxy)phenyl)propanamide

[0174]

[0175] According to the synthesis method of intermediate-2, the starting material benzaldehyde was replaced with p-trifluoromethoxybenzaldehyde to obtain compound 37: 2-oxo-3-(4-(trifluoromethoxy)phenyl)propanoic acid. The total yield of the two steps was 62.3%. HRMS (ESI - ): Calculated value C 10 H9O3(MH) - ,177.0557; measured value 177.0568.

[0176] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 37 to obtain compound 38; compound 32 was replaced by compound 38 to obtain yellow-white solid NX-4 (0.11 g, yield 22.0%, purity 99.33%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.10 (s, 1H), 8.56 (t, J = 6.4Hz, 1H), 7.83 (d, J = 7.8Hz, 1H), 7.45 (s, 1H), 7.35-7.19 (m, 3H), 6.99-6.87 (m, 2H), 6.28 (s ,2H),5.11(dd,J=13.3,5.1Hz,1H),4.46-4.20(m,4H),3.84(s,2H),3.00- 2.83(m,1H),2.59(d,J=17.0Hz,1H),2.47-2.30(m,1H),2.09-1.94(m,1H). HRMS(ESI + ): Calculated value C 24 H 23 F3N5O5(M+H) + ,518.1646; measured value 518.1642.

[0177] Example 18 Synthesis of Compound NX-5: 3-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxopropanamide

[0178]

[0179] According to the synthesis method of intermediate-2, the starting material benzaldehyde was replaced with p-chlorobenzaldehyde to obtain compound 39: 3-(4-chlorophenyl)-2-oxopropanoic acid. The total yield of the two steps was 52.4%. HRMS (ESI - ): Calculated value C9H6ClO3(MH) - ,197.0011; measured value 197.0021.

[0180] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 39 to obtain compound 40; compound 32 was replaced by compound 40 to obtain yellow-white solid NX-5 (0.14 g, yield 28.0%, purity 97.90%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 10.95 (s, 1H), 8.40 (t, J = 6.4Hz, 1H), 7.88 (d, J=7.8Hz,1H),7.48(s,1H),7.40-7.29(m,3H),7.22(d,J=7.8Hz,2H),6.33( s,2H),5.11(dd,J=13.3,5.1Hz,1H),4.49-4.23(m,4H),3.80(s,2H),3.02- 2.84(m,1H),2.60(d,J=17.7Hz,1H),2.47-2.33(m,1H),2.07-1.93(m,1H). HRMS(ESI + ): Calculated value C 23 H 23 ClN5O4(M+H) + ,468.1433; measured value 468.1427.

[0181] Example 19: Synthesis of Compound NX-6: N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxo-3-(4-(trifluoromethyl)phenyl)propanamide

[0182]

[0183] According to the synthesis method of intermediate-2, the starting material benzaldehyde was replaced with p-trifluoromethylbenzaldehyde to obtain compound 41: 2-oxo-3-(4-(trifluoromethyl)phenyl)propionic acid. The total yield of the two steps was 53.6%. HRMS (ESI - ): Calculated value C 10 H6F3O3(MH) - ,231.0275; measured value 231.0268.

[0184] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 41 to obtain compound 42; compound 32 was replaced by compound 42 to obtain light yellow solid NX-6 (0.10 g, yield 20.0%, purity 97.51%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.01 (s, 1H), 8.49 (t, J = 6.3 Hz, 1H), 7.83 (d, J =7.8Hz,1H),7.55-7.43(m,3H),7.37-7.29(m,2H),7.19(d,J=7.0Hz,1H),6. 28(s,2H),5.11(dd,J=13.3,5.1Hz,1H),4.51-4.25(m,4H),3.85(s,2H),2.9 8-2.85(m,1H),2.58(d,J=17.0Hz,1H),2.47-2.32(m,1H),2.10-1.94(m,1H). HRMS(ESI + ): Calculated value C 24 H 23 F3N5O4(M+H) + ,502.1697; measured value 502.1694.

[0185] Example 20: Synthesis of Compound NX-7: 3-(3-chloro-4-methylphenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxopropanamide

[0186]

[0187] According to the synthesis method of intermediate-2, the starting material benzaldehyde was replaced with 3-chloro-4-methylbenzaldehyde to obtain compound 43: 3-(3-chloro-4-methylphenyl)-2-oxopropionic acid. The total yield of the two steps was 58.2%. HRMS (ESI - ): Calculated value C 10 H8ClO3(MH) - ,211.0167; measured value 211.0159.

[0188] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 43 to obtain compound 44; compound 32 was replaced by compound 44 to obtain light yellow-white solid NX-7 (0.15 g, yield 30.0%, purity 97.31%). 1H NMR (400MHz, DMSO-d6) δ (ppm) 11.02 (s, 1H), 8.37 (t, J = 6.4Hz, 1H), 7.66 (d, J = 7.8Hz ,1H),7.43(s,1H),7.40-7.32(m,3H),7.25(s,1H),7.23(d,J=7.8Hz,1H),7.09(d,J= 9.5Hz,1H),5.11(dd,J=13.3,5.1Hz,1H),4.51-4.21(m,4H),3.75(s,2H),2.96-2.8 5(m,1H),2.60(d,J=17.3Hz,1H),2.45-2.31(m,1H),2.26(s,3H),2.03-1.94(m,1H). HRMS(ESI + ): Calculated value C 24 H 25 ClN5O4(M+H) + ,482.1590; measured value 482.1578.

[0189] Example 21: Synthesis of Compound CX-1: (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)-3-phenylpropanamide

[0190]

[0191] Dissolve (E)-2-(Methoxyimino)-3-phenylpropionic acid (Intermediate-4, 0.31 g, 1.62 mmol) in 6 mL of N,N-dimethylformamide, add EDCI (0.38 g, 2.02 mmol) and HOBT (0.27 g, 2.02 mmol) in turn, stir at room temperature for 1 hour, add 3-(5-aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (Intermediate-1, 0.25 g, 0.81 mmol), and stir at room temperature overnight. The reaction was completed as monitored by TLC, and the reaction solution was poured into 30 mL of water and extracted with ethyl acetate. The organic phases were combined and washed with water and saturated brine in sequence, dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by silica gel chromatography (dichloromethane: methanol = 60: 1, v / v) to give an off-white solid CX-1 (0.08 g, 22.2%, purity 97.85%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.05 (s, 1H), 9.08 (t, J = 6.1Hz, 1H), 7.86 (d, J = 7.8Hz, 1H), 7.52 (s, 1H), 7.35-7.10 (m, 6H), 5.11 (dd, J = 13.3 ,5.0Hz,1H),4.50-4.23(m,4H),3.98(s,3H),3.85(s,2H),3.00-2.83(m,1H),2.60(d,J=17.3Hz,1H),2.46-2.34(m,1H),2.08-1.95(m,1H). HRMS(ESI + ): Calculated value C 24 H 25 N4O5(M+H) + ,449.1820; measured value 449.1816.

[0192] Example 22: Synthesis of Compound CX-2: (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)-3-(p-tolyl)propionamide

[0193]

[0194] According to the synthetic method of intermediate-2 and intermediate-4, the starting material benzaldehyde was replaced with p-methylbenzaldehyde to obtain compound 45: (E)-2-(methoxyimino)-3-(p-tolyl)propionic acid. The total yield of the three steps was 62.5%. HRMS (ESI - ): Calculated value C 11 H 12 NO3(MH) - ,206.0823; measured value 206.0835.

[0195] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 45 to obtain an off-white solid CX-2 (0.11 g, yield 29.7%, purity 98.34%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.00 (s, 1H), 8.99 (t, J = 6.1Hz, 1H), 7.95 (d, J = 7.8Hz, 1H),7.52(s,1H),7.35(d,J=7.7Hz,2H),7.20(d,J=7.8Hz,1H),7.05(d,J=7.5Hz,2H) ,5.11(dd,J=13.3,5.0Hz,1H),4.52-4.25(m,4H),3.95(s,3H),3.82(s,2H),2.99-2. 81(m,1H),2.60(d,J=17.7Hz,1H),2.47-2.31(m,1H),2.23(s,3H),2.08-1.92(m,1H). HRMS(ESI + ): Calculated value C 25 H 27 N4O5(M+H) + ,463.1976; measured value 463.1972.

[0196] Example 23 Compound CX-3: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(4-fluorophenyl)-2-(methoxyimino)propionamide

[0197]

[0198] According to the synthesis method of intermediate-2 and intermediate-4, the starting material benzaldehyde was replaced with p-fluorobenzaldehyde to obtain compound 46: (E)-3-(4-fluorophenyl)-2-(methoxyimino)propionic acid. The total yield of the three steps was 65.3%. HRMS (ESI - ): Calculated value C 10 H9FNO3(MH) - ,210.0572; measured value 210.0568.

[0199] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced by compound 46 to obtain white solid CX-3 (0.13 g, yield 34.4%, purity 99.19%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 10.99 (s, 1H), 8.89 (t, J = 6.1Hz, 1H), 7.92 (d, J=7.6Hz,1H),7.55(s,1H),7.35-7.25(m,3H),7.05(t,J=8.9Hz,2H),5.11( dd,J=13.3,5.0Hz,1H),4.50-4.25(m,4H),3.97(s,3H),3.78(s,2H),3.00- 2.83(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.32(m,1H),2.08-1.95(m,1H). HRMS(ESI + ): Calculated value C 24 H 24 FN4O5(M+H) + ,467.1725; measured value 467.1720.

[0200] Example 24 Compound CX-4: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(3-fluorophenyl)-2-(methoxyimino)propionamide

[0201]

[0202] According to the synthesis method of intermediate-2 and intermediate-4, the starting material benzaldehyde was replaced with 3-fluorobenzaldehyde to obtain compound 47: (E)-3-(3-fluorophenyl)-2-(methoxyimino)propionic acid. The total yield of the three steps was 55.7%. HRMS (ESI - ): Calculated value C 10 H9FNO3(MH) - ,210.0572; measured value 210.0563.

[0203] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced by compound 47 to obtain an off-white solid CX-4 (0.10 g, yield 26.5%, purity 98.62%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.05 (s, 1H), 8.86 (t, J = 6.1 Hz, 1H), 7.88 (d, J = 7. 6Hz,1H),7.48(s,1H),7.35-7.26(m,2H),7.15(d,J=7.5Hz,2H),7.05-6.94(m,1 H),5.11(dd,J=13.3,5.0Hz,1H),4.45-4.21(m,4H),3.95(s,3H),3.82(s,2H),3 .02-2.85(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.32(m,1H),2.10-1.95(m,1H). HRMS(ESI + ): Calculated value C 24 H 24 FN4O5(M+H) + ,467.1725; measured value 467.1718.

[0204] Example 25 Compound CX-5: Synthesis of (E)-3-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)propionamide

[0205]

[0206] According to the synthesis method of intermediate-2 and intermediate-4, the starting material benzaldehyde was replaced with p-chlorobenzaldehyde to obtain compound 48: (E)-3-(4-chlorophenyl)-2-(methoxyimino)propionic acid. The total yield of the three steps was 59.6%. HRMS (ESI - ): Calculated value C 10 H9ClNO3(MH) - ,226.0276; measured value 226.0268.

[0207] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 48 to obtain white solid CX-5 (0.10 g, yield 25.6%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 10.90 (s, 1H), 9.05 (t, J = 6.1Hz, 1H), 7.76 (d, J=7.6Hz,1H),7.50(s,1H),7.36-7.28(m,3H),7.16(t,J=8.9Hz,2H),5.11( dd,J=13.3,5.0Hz,1H),4.52-4.28(m,4H),3.95(s,3H),3.79(s,2H),2.97- 2.82(m,1H),2.60(d,J=17.0Hz,1H),2.47-2.32(m,1H),2.08-1.96(m,1H). HRMS(ESI + ): Calculated value C 24 H 24 ClN4O5(M+H) + ,483.1430; measured value 483.1428.

[0208] Example 26 Compound CX-6: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)-3-(4-(trifluoromethyl)phenyl)propanamide

[0209]

[0210] According to the synthesis method of intermediate-2 and intermediate-4, the starting material benzaldehyde was replaced with p-trifluoromethylbenzaldehyde to obtain compound 49: (E)-2-(methoxyimino)-3-(4-(trifluoromethyl)phenyl)propanoic acid. The total yield of the three steps was 61.3%. HRMS (ESI - ): Calculated value C 11 H9F3NO3(MH) - ,260.0540; measured value 260.0537.

[0211] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 49 to obtain a gray solid CX-6 (0.09 g, yield 21.4%, purity 98.42%). 1H NMR(300MHz,DMSO-d6)δ(pp m)11.00(s,1H),8.94(t,J=6.1Hz,1H),7.80(d,J=7.6Hz,1H),7.52-7.44(m,3H),7.33-7.21(m,3H),5.11(dd,J=13.3,5.0Hz,1H ),4.50-4.25(m,4H),3.99(s,3H),3.75(s,2H),2.98-2.83(m,1H),2.61(d,J=17.3Hz,1H),2.48-2.33(m,1H),2.10-1.96(m,1H). HRMS(ESI + ): Calculated value C 25 H 24 F3N4O5(M+H) + ,517.1694; measured value 517.1691.

[0212] Example 27 Compound CX-7: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)-3-(4-(trifluoromethoxy)phenyl)propanamide

[0213]

[0214] According to the synthesis method of Intermediate-2 and Intermediate-4, the starting material benzaldehyde was replaced with p-trifluoromethoxybenzaldehyde to obtain compound 50: (E)-2-(methoxyimino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid. The total yield of the three steps was 62.5%. HRMS (ESI - ): Calculated value C 11 H9F3NO4(MH) - ,276.0489; measured value 276.0475.

[0215] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced by compound 50 to obtain off-white solid CX-7 (0.08 g, yield 18.6%, purity 98.66%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.00 (s, 1H), 8.94 (t, J = 6.1Hz, 1H), 7.80 (d, J = 7.6 Hz,1H),7.49(s,1H),7.34(d,J=7.2Hz,1H),7.21(d,J=7.0Hz,2H),6.90(d,J=7.5H z,2H),5.11(dd,J=13.3,5.0Hz,1H),4.46-4.24(m,4H),3.98(s,3H),3.78(s,2H) ,3.01-2.83(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.32(m,1H),2.07-1.96(m,1H). HRMS(ESI + ): Calculated value C 25 H 24 F3N4O6(M+H) + ,533.1643; measured value 533.1636.

[0216] Example 28 Compound CX-8: Synthesis of (E)-3-(3-chloro-4-methylphenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)propionamide

[0217]

[0218] According to the synthesis method of Intermediate-2 and Intermediate-4, the starting material benzaldehyde was replaced with 3-chloro-4-methylbenzaldehyde to obtain compound 51: (E)-3-(3-chloro-4-methylphenyl)-2-(methoxyimino)propionic acid. The total yield of the three steps was 65.6%. HRMS (ESI - ): Calculated value C 11 H 11 ClNO3(MH) - ,240.0433; measured value 240.0438.

[0219] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 51 to obtain white solid CX-8 (0.13 g, yield 32.5%, purity 99.92%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.00 (s, 1H), 8.86 (d, J = 6.6Hz, 1H), 7.65 (d, J = 7.8Hz, 1H) ,7.40(s,1H),7.35(d,J=7.7Hz,1H),7.25(d,J=7.8Hz,1H),7.19(s,1H),7.05(d,J=7.9H z,1H),5.11(dd,J=13.3,5.0Hz,1H),4.52-4.21(m,4H),3.98(s,3H),3.80(s,2H),3.00- 2.81(m,1H),2.61(d,J=15.3Hz,1H),2.45-2.34(m,1H),2.27(s,3H),2.08-1.92(m,1H). HRMS(ESI + ): Calculated value C 25 H 26 ClN4O5(M+H) + ,497.1586; measured value 497.1582.

[0220] Example 29 Compound CX-9: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(4-fluorophenyl)-2-(methoxyimino)acetamide

[0221]

[0222] According to the synthesis method of Intermediate-4, the starting material Intermediate-2 was replaced with 2-(4-fluorophenyl)-2-oxoacetic acid to obtain Compound 52: (Z)-2-(4-fluorophenyl)-2-(methoxyimino)acetic acid with a yield of 78.3%. HRMS (ESI - ): Calculated value C9H7FNO3(MH) - ,196.0415; measured value 196.0425.

[0223] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced by compound 52 to obtain yellow-white solid CX-9 (0.09 g, yield 25.0%, purity 96.88%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.01 (s, 1H), 9.34 (t, J = 6.1Hz, 1H), 7.73 (d, J = 7.9Hz, 1H), 7.65-7.54 (m, 3H), 7.50 (d, J = 7.9Hz, 1H), 7.30 (t, J = 8.9Hz ,2H),5.13(dd,J=13.2,5.1Hz,1H),4.63-4.26(m,4H),3.96(s,3H),3.00- 2.85(m,1H),2.61(d,J=17.4Hz,1H),2.45-2.33(m,1H),2.07-1.97(m,1H). HRMS(ESI + ): Calculated value C 23 H 22 FN4O5(M+H) + ,453.1569; measured value 453.1568.

[0224] Example 30 Compound CX-10: Synthesis of (E)-2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)acetamide

[0225]

[0226] According to the synthesis method of Intermediate-4, the starting material Intermediate-2 was replaced with 2-(4-fluorophenyl)-2-oxoacetic acid to obtain Compound 53: (Z)-2-(4-chlorophenyl)-2-(methoxyimino)acetic acid with a yield of 75.6%. HRMS (ESI - ): Calculated value C9H7ClNO3(MH) - ,212.0120; measured value 212.0131.

[0227] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced by compound 53 to obtain a light yellow solid CX-10 (0.10 g, yield 26.3%, purity 98.12%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.05 (s, 1H), 9.25 (t, J = 6.1Hz, 1H), 7.79 (d, J = 7.9Hz, 1H), 7.66-7.54 (m, 3H), 7.48 (d, J = 7.9Hz, 1H), 7.25 (t, J = 8.9Hz ,2H),5.11(dd,J=13.2,5.1Hz,1H),4.55-4.26(m,4H),3.90(s,3H),2.98- 2.82(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.33(m,1H),2.08-1.99(m,1H). HRMS(ESI + ): Calculated value C 23 H 22 ClN4O5(M+H) + ,469.1273; measured value 469.1269.

[0228] Example 31 Compound CX-11: Synthesis of (E)-2-(2-aminothiazol-4-yl)-N-((2-(2,6-dioxopyrimidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)acetamide hydrochloride

[0229]

[0230] Step 1: Dissolve (E)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetic acid (compound 54, 0.5 g, 2.48 mmol) in a mixed solvent of 4 mL of N,N-dimethylformamide and 10 mL of tetrahydrofuran, add dropwise 4 mL of a tetrahydrofuran solution of sodium bis(trimethylsilyl)amide (2 M) under ice bath, stir under ice bath for 1 h, add dropwise di-tert-butyl dicarbonate (0.58 g, 2.68 mmol) at 0°C, stir under room temperature for 2 h. The reaction was completed as monitored by TLC, and the reaction solution was concentrated in vacuo. The residue was poured into 20 mL of water and the pH was adjusted to 3-4 with dilute hydrochloric acid (3 M) to precipitate a yellow-white solid. The solid was allowed to stand for complete precipitation, and then filtered off with suction and the filter cake was dried to obtain a light yellow solid 55: (E)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(methoxyimino)acetic acid (0.26 g, yield 34.6%).

[0231] Step 2: Dissolve 3-(5-aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (Intermediate-1, 0.15 g, 0.49 mmol) in 6 mL of N,N-dimethylformamide, add compound 55 (0.15 g, 0.49 mmol) and HATU (0.28 g, 0.74 mmol) in turn, stir at room temperature for 1 hour after addition, add DIPEA (0.19 g, 1.47 mmol), and stir at room temperature overnight. The reaction was completed as monitored by TLC. The reaction solution was poured into 30 mL of ice water to precipitate a brown solid. The solution was allowed to stand for complete precipitation and filtered. The filter cake was purified using a silica gel column (dichloromethane:methanol=50:1, v / v) to give a brown-yellow solid 56: (E)-tert-butyl (4-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-1-(methoxyimino)-2-oxoethyl)thiazol-2-yl)carbamate (0.11 g, yield 40.7%).

[0232] Step 3: Compound 56 (0.11 g, 0.19 mmol) was dissolved in 30 mL of hydrochloric acid-dioxane solution (4 M) and stirred at room temperature for 3 hours. The reaction was completed as monitored by TLC, and the filter cake was vacuum-dried to obtain a light yellow solid CX-11 (0.04 g, yield 45.9%, purity 98.87%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.01 (s, 1H), 9.08 (t, J = 6.1Hz, 1H), 7.95 (s, 1H), 7.74 (d, J = 7.8Hz, 1H), 7.56 (s, 1H), 7.49 (d, J = 7.9Hz, 1H), 7.26 (s, 2H),5.13(dd,J=13.3,5.0Hz,1H),4.53-4.28(m,4H),3.99(s,3H),3.01-2 .85(m,1H),2.60(d,J=19.1Hz,1H),2.45-2.30(m,1H),2.07-1.96(m,1H). HRMS(ESI + ): Calculated value C 20 H 21 N6O5S(M+H) + ,457.1289; measured value 457.1278.

[0233] Biological test example 1: Study on the degradation of GSPT1 in KG-1 cells

[0234] KG-1 cells (ATCC) were grown in IMDM (containing 20% ​​FBS) and the cell concentration was adjusted to 10 6Cells / well were plated in 6-well plates, 1350 μl per well. 150 μl of DMSO and the test compound of the present invention were added, the compound concentration was 200 nM, and the cells were cultured in a 5% CO2, 37°C incubator for 4 hours. The cells were centrifuged to discard the culture medium, and PBS was added for washing and discarded. Whole-cell lysates were prepared using a mixture of protease inhibitors (100×, Ford Biotechnology), a mixture of protein phosphatase inhibitors (100×, Ford Biotechnology), super nuclease (Biyuntian) and high-strength RIPA lysis buffer (Thermo Fisher), and placed on ice for 30 minutes. Centrifuge to discard the cell debris precipitate, collect the supernatant whole-cell lysate and transfer it to a new centrifuge tube. After the BCA protein assay, 5X loading buffer (Thermo Fisher) was used to prepare the sample. The samples were electrophoresed in 4-20% precast gel (SDS-PAGE gel) to separate proteins, then transferred to PVDF membrane and blocked with 5% NFDM / TBST at room temperature for 1 hour, incubated with primary antibody at 4°C overnight, and incubated with secondary antibody at room temperature for 2 hours the next day. The signal was detected using MINICHEM™ imaging system.

[0235] The control group was a blank solvent group.

[0236] The following antibodies were used in this test case:

[0237] Primary Antibody:

[0238] Anti-GSPT1: Abcam ab234433

[0239] Anti-IKZF1:Cell signaling technology(CST)5443S

[0240] Anti-IKZF3:Cell signaling technology(CST)15103S

[0241] Anti-beta Actin: Fude Bio FD0060

[0242] Secondary Antibody:

[0243] Anti-rabbit peroxidase-linked secondary antibody: FDG007

[0244] The degradation effects of the compounds on GSPT1 protein are shown in Table 1, wherein A indicates that the degradation percentage of GSPT1 protein is not less than 80%, B indicates that the degradation percentage is less than 80% but not less than 50%, C indicates that the degradation percentage is less than 50% but not less than 25%, and D indicates that the degradation percentage is less than 25%.

[0245] Table 1 Degradation of GSPT1 protein by compounds

[0246]

[0247]

[0248] As can be seen from the table, compared with the clinical drug CC-90009, the degradation effect of the dominant compounds in each series of compounds of the present invention is better than that of the clinical drug, and the degradation effect of most other compounds is comparable to that of the clinical drug. It can be seen that the degradation effect of the oxime compounds OX, NX, and CX series on GSPT1 protein can be significantly improved.

[0249] The present invention takes compound OX-7 as an example, and provides a graph showing that its degradation of GSPT1 in AML cells is concentration-dependent and time-dependent, see Figure 1 , Figure 2 .in, Figure 1 A is the degradation effect of compound OX-7 and clinical drug CC-90009 on GSPT1 in KG-1 cells. Figure 1 B shows the degradation effect of compound OX-7 and clinical drug CC-90009 on GSPT1 in MOLM-13 cells.

[0250] As can be seen from the figure, the degradation effect of the compound OX-7 of the present invention on GSPT1 in KG-1 and MOLM-13 cells is concentration-dependent and time-dependent, and the effect is more significant than that of CC-90009.

[0251] Biological test example 2: Anti-KG-1 cell proliferation activity of the compounds of the present invention

[0252] KG-1 cells in the logarithmic growth phase were diluted with culture medium (RPMI + 10% FBS), plated in 96-well plates at 5000 cells / well, and cultured in a 5% CO2, 37°C incubator for 24 hours. The test compound of the present invention was prepared into a 10mM stock solution with DMSO, diluted with culture medium to set 9 concentration gradients, with 3 replicates for each concentration, and cultured in a 5% CO2, 37°C incubator for 72 hours after drug addition. Cell proliferation was detected using the CCK8 method. The IC value of the compound's inhibition of cell growth was determined using the enzyme labeling method. 50 IC values ​​were calculated using GraphPad Prism 7 software. 50 value.

[0253] The anti-KG-1 cell proliferation activities of the compounds are shown in Table 2, where A represents IC 50 <1nM, B means 1≤IC 50 <10nM, C means 10nM≤IC 50 <100nM, D means 100nM≤IC50 <1000nM, E represents IC 50 ≥1000nM.

[0254] Table 2 Anti-KG-1 cell proliferation activity of compounds

[0255] Compound <![CDATA[IC 50 ]]> Compound <![CDATA[IC 50 ]]> OX-1 C NX-4 D OX-2 C NX-5 E OX-3 C NX-6 C OX-4 C NX-7 B OX-5 E CX-1 E OX-6 D CX-2 D OX-7 B CX-3 D OX-8 C CX-4 C OX-9 C CX-5 C OX-10 C CX-6 C OX-11 D CX-7 B OX-12 D CX-8 B OX-13 D CX-9 D NX-1 E CX-10 D NX-2 C CX-11 D NX-3 E CC-90009 C

[0256] From the antiproliferative activity of each series of compounds in the table, it can be seen that the antiproliferative inhibitory activity of the compounds OX, NX, and CX series of the present invention on KG-1 cells is significantly improved, which is better than the clinical drug CC-90009. Among them, the superior compounds of each series such as OX-7, NX-7, CX-7, and CX-8 have excellent antiproliferative inhibitory activity, IC 50 Biological test example 3: The compounds of the present invention have antiproliferative activity against various tumor cells

[0257] U937, MOLM-13, and MV4-11 cells (ATCC) in the logarithmic growth phase were diluted with culture medium, plated in 96-well plates at 5000 cells / well, and cultured in a 5% CO2, 37°C incubator for 24 hours. The compound was prepared into a 10mM stock solution with DMSO, diluted with culture medium to set up 9 concentration gradients, with 3 replicates for each concentration, and cultured in a 5% CO2, 37°C incubator for 72 hours after drug addition. Cell proliferation was detected using the CCK8 method. The IC value of the compound on cell growth inhibition was determined by enzyme labeling. 50 IC values ​​were calculated using GraphPad Prism 7 software. 50 value.

[0258] The anti-tumor cell proliferation activities of the compounds are shown in Table 3, where A represents IC 50 <1nM, B means 1≤IC 50 <10nM, C means 10nM≤IC 50 <100nM, D means 100nM≤IC 50 <1000nM, E represents IC 50 ≥1000nM.

[0259] Table 3 Anti-tumor cell proliferation activity of compounds

[0260] Compound U937 MOLM-13 MV4-11 OX-2 C B C OX-7 B B B NX-2 D C C NX-7 C C C CX-7 B D C CX-8 B C B CC-90009 C D C

[0261] As can be seen from the table, compared with the clinical drug CC-90009, the antiproliferative inhibitory activity of the dominant compounds in each series of compounds of the present invention is better than CC-90009, and the other compounds are also comparable to CC-90009. Therefore, it can be seen that the antiproliferative inhibitory activity of the oxime compounds OX, NX, and CX series of the present invention on various AML cells is significantly improved.

[0262] As described above, although the present invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the present invention itself. Various changes in form and details may be made without departing from the spirit and scope of the present invention as defined in the appended claims.

Claims

1. A compound represented by the general formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, diastereomer thereof: in: X is selected from -OH, -NH 2 、-OCH 3 or -NHCOCH 3 ; Ring Y is selected from C 6 -C 12 Aryl, 5-10 membered heteroaryl, C 3 -C 8 Cycloalkyl or 3-10 membered heterocyclyl, the aryl, heteroaryl, cycloalkyl and heterocyclyl are unsubstituted or optionally substituted with 1-3 R a replace; R 1 Selected from R 2 Selected from hydrogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O) 2 R a or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is unsubstituted or optionally substituted with 1-3 R a replace; Each R 3 are independently selected from hydrogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O) 2 R a or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is unsubstituted or optionally substituted with 1-3 R a replace; R 4 Selected from hydrogen, deuterium, halogen or C 1 -C 6 alkyl; R 5 Selected from hydrogen, deuterium, C 1 -C 12 alkyl, Z is selected from -CH 2 -, -CD 2 -, -C(O)- or -C(S)-; R 6 , R 7 , R 8 , R 9 , R 10 , R 11 are independently selected from hydrogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O) 2 R a or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is unsubstituted or optionally substituted with 1-3 R a replace; Each R a , R b are independently selected from hydrogen, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, hydroxy, cyano, nitro, benzyl, -C(O)NR c R d 、-C(O)R c 、-C(O)OR c 、-OR c 、-OC(O)R c 、-OC(O)OR c 、-OC(O)NR c R d 、-NR c R d 、-SR c 、-S(O)R c 、-S(O) 2 R c or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or benzyl group is unsubstituted or optionally substituted with 1-3 R c replace; Each R c , R d are independently selected from hydrogen, halogen, carbonyl, hydroxyl, cyano, nitro, phenyl, benzyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, halogenated C 1 -C 6 Alkoxy, C 3 -C 6 Cycloalkyl or halogenated C 3 -C 6 Cycloalkyl; m, n, and p are independently selected from 0, 1, 2 or 3.

2. The compound according to claim 1, which has a structure of Formula Ia, Formula Ib or Formula Ic: in, X, Y, Z, m, n, and p are as defined in Formula I.

3. The compound according to claim 1 or 2, Features: X is selected from -OH, -NH 2 or -OCH 3 .

4. The compound according to claim 1, Features: R 2 Selected from hydrogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O) 2 R a ; R a , R b are independently selected from hydrogen, C 1 -C 6 Alkyl or -C(O)R c ; R c Selected from hydrogen, halogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, halogenated C 1 -C 6 Alkoxy or C 3 -C 6 Cycloalkyl; Ring Y is selected from C 6 -C 12 Aryl or 5-10 membered heteroaryl.

5. The compound according to claim 4, Features: R 3 Selected from hydrogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 alkynyl, halogen, cyano or nitro; R 4 Selected from hydrogen, deuterium, halogen or C 1 -C 6 alkyl; R 5 Selected from hydrogen, deuterium or C 1 -C 12 alkyl; m and n are independently selected from 1; p is selected from 0 or 1.

6. The compound according to claim 1, Features Selected from:

7. A pharmaceutical composition, It is characterized in that A therapeutically effective amount of a compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt, tautomer, mesoform, racemate, enantiomer, diastereomer thereof, and a pharmaceutically acceptable carrier or excipient.

8. Use of the compound according to any one of claims 1 to 6 in the preparation of a medicament for treating or preventing diseases associated with GSPT1, IKZF1, IKZF2, IKZF3, CK1α, N-MYC or C-MYC protein mutations, expression imbalances, conformational changes and functional abnormalities.

9. The use according to claim 8, It is characterized in that The related diseases are cancer, viral infection, aging, immune diseases, and neurological diseases; wherein the cancer is selected from acute myeloid leukemia, liver cancer, acute lymphocytic leukemia, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, chronic lymphocytic leukemia CLL, chronic myeloid leukemia CML, colon cancer, esophageal cancer, gallbladder cancer, gastric cancer, gastrointestinal stromal tumors, head and neck cancer, Hodgkin's lymphoma, laryngeal cancer, leukemia, lung cancer, melanoma, mesothelioma, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, kidney cancer, sarcoma, skin cancer, small cell lung cancer, testicular cancer, pharyngeal cancer, thyroid cancer or uterine cancer.

10. Use of the compound according to any one of claims 1 to 6 in the preparation of a GSPT1 degrading agent.